Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Adverum Biotechnologies

ArQule

Here's how they could keep on rocketing higher.

3 Soaring Biotech Stocks to Watch in December

Arrowhead Pharmaceuticals grabbed an upgrade Friday as ARWR stock has rocketed 144% since October on enthusiasm for the biotech company's RNAi platform. ARWR stock is 87% above a buy point.

This Biotech With 456% Growth In 2019 Just Gained A Price-Target Boost

The gene-silencing specialist reported fiscal 2019 operating results and listed recent accomplishments.

Here's Why Arrowhead Pharmaceuticals Is Soaring (Again) Today

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2019 Results - Earnings Call Transcript

Lyft

Ferro

These stocks climbed more than most on a winning day on Wall Street.

Why Lyft, Arrowhead Pharmaceuticals, and Ferro Jumped Today

Clovis Oncology

Dicerna Pharmaceuticals

Medicines

Sorrento Therapeutics Inc

A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?

The Return of M&A Activity Is Lifting These Biotech Stocks Today

Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last month. The company currently has a pipeline of 9 drugs under clinical trials.

Why Arrowhead Pharma Stock Has Rallied 30% Over The Last Month

Amarin Corporation Plc

Inmode Ltd

InMode, Amarin, and Arrowhead Pharmaceuticals are small-cap healthcare stocks working wonders right now.

3 Top Healthcare Stocks to Buy in November

Assembly Biosciences

Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.

2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors

As the health care sector breaks higher, Arrowhead is in a leadership position, and buy signals suggest additional upside potential.

Arrowhead Shares Are Still Alerting Big Buy Signals

Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.

Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

Arrowhead Pharma stock flirted with a breakout Friday after the biotech company said it's experimenting with silencing multiple genes as well as moving into diseases outside the liver.

This Biotech Stock Hurdled A Genetic Barrier — And Flirted With A Breakout

The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.

Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August

Arrowhead Pharmaceuticals stock flirted with a breakout Thursday after earning a $25 million milestone payment as its hepatitis B treatment with Johnson & Johnson begins midstage testing.
The post Why This Newly Profitable Biotech Stock Is Flirting With A Breakout appeared first on Investor's Business Daily.

Why This Newly Profitable Biotech Stock Is Flirting With A Breakout

Shares are trading hands at their highest level in years, and have posted a three-year return of over 350%.

Arrowhead Pharmaceuticals: Buy at the High?

The best days are likely ahead for Arrowhead Pharmaceuticals, and institutional buy signals indicate upside potential for the shares.

Arrowhead Pharma Shares Quietly See Big Buy Demand

Key price target upgrades in the analyst community follow Arrowhead's latest impressive earnings call.

Arrowhead Pharmaceuticals: Highlights Of A Terrific Earnings Call

There was plenty of pipeline progress for the clinical-stage biotech in the third quarter.

What You'll Want to Know About Arrowhead Pharmaceuticals' Q3 Update

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2019 Results - Earnings Call Transcript

Johnson & Johnson

World Hepatitis Day inspired Janssen Sciences to reaffirm its commitment to eliminate the threat by 2030.

Arrowhead Pharmaceuticals - Janssen Collaboration Could Be A Game Changer

An outstanding 100% of patients achieved ≥1.0 Log10 IU/mL HBsAg reduction in ARO-HBV’s phase 1/2 interim trial results.

Why Arrowhead's Promising Gene Silencing Technology Makes The Stock A Strong Buy

RNA medicines are a 21st Century wealth generator.

Arrowhead Pharmaceuticals RNA Therapy Pipeline Is Promising

Arrowhead Pharmaceuticals slumped on a downgrade Friday after breaking out in mid-May and running up 39%. But the Food and Drug Administration granted it fast track for a liver disease drug.

Highly Rated Biotech Downgraded After Breaking Out And Running 39%

Arrowhead was able to get FDA to allow phase 2/3 study to be a pivotal one in which two histological endpoints could be used to gain accelerated approval for ARO-ATT.

Arrowhead Looks To Get Rare Liver Disease Drug Approved With Use Of Accelerated Approval

Arrowhead's most recent share price run has left investors wondering if it has run too far too fast.

News for Arrowhead Pharmaceuticals Stock (ARWR)